INNOVATION & RESEARCH

Precision fermentation has proven it can make animal-identical dairy proteins in a lab. The next question, and arguably the harder one, is whether the industry can make them cheaply enough, and fast enough, to matter commercially.

Key Takeaways

• The biology is largely solved. The competitive battleground has shifted to titre, bioprocess efficiency and manufacturing cost.
• 21st.Bio’s beta-lactoglobulin reached self-affirmed GRAS status in under two years, an unusually fast regulatory timeline its licensing model may help replicate for other developers.
• At least five companies, including Perfect Day, Remilk, Imagindairy, Vivici and 21st.Bio, are targeting beta-lactoglobulin specifically, signalling convergence around a small set of proteins rather than broad novel discovery.
• Precision-fermented dairy proteins currently suit premium, functionality-driven applications such as sports and medical nutrition more than commodity-scale substitution, given persistent cost and volume gaps versus conventional dairy.

A growing body of evidence suggests the answer depends less on biology and more on engineering, regulatory speed and infrastructure choices that determine whether a promising strain ever reaches a factory floor.

The Science Is No Longer the Bottleneck

Milk proteins such as beta-lactoglobulin, alpha-lactalbumin and caseins can now be produced through engineered yeast and fungal hosts with reasonable fidelity to their animal-derived counterparts. Advances in synthetic biology, metabolic engineering and bioreactor design have made secreted recombinant protein production increasingly routine, at least at pilot scale.

Danish company 21st.Bio offers a useful data point. Its beta-lactoglobulin ingredient, BLG Essential+, went from initial strain development to self-affirmed GRAS status in the United States in under two years, a notably fast regulatory timeline for a novel food ingredient. The company has since expanded into alpha-lactalbumin and caseins, licensing production strains partly developed with Novonesis, one of the industry’s established biosolutions players.

The broader competitive landscape reinforces the point. Perfect Day, Remilk, Imagindairy and the Netherlands’ Vivici have all pursued beta-lactoglobulin as a flagship target, with Vivici commercially launching its Vivitein BLG in March 2025. When five or more companies converge on the same protein, it signals the biology is largely solved. What differentiates them now is production economics.

Titre Is the Real Currency

In precision fermentation, the number that matters most to investors and manufacturers alike is titre, the concentration of target protein a given microorganism produces per litre of fermentation broth. Higher titres mean less fermentation capacity, less downstream processing and lower cost per kilogram of finished ingredient.

This is why so much competitive activity centres on strain optimization rather than novel protein discovery. Companies are not racing to find new proteins to make. They are racing to make the same handful of high-value proteins, chiefly beta-lactoglobulin, more efficiently than their rivals. That distinction matters for anyone evaluating this space: the differentiator is bioprocess engineering, not biological novelty.

Regulatory Speed Is Becoming a Competitive Asset

21st.Bio’s under-two-year path to GRAS status is also notable because regulatory timelines have historically been one of precision fermentation’s biggest commercial risks. A business model built partly around licensing an existing GRAS determination to multiple customers, rather than each company independently repeating the regulatory process, could meaningfully shorten the runway between strain development and market entry.

Whether this licensing approach becomes an industry norm or remains one company’s competitive advantage is worth watching. If it spreads, the bottleneck for new entrants shifts further away from regulation and further toward manufacturing capacity and capital.

What This Means for Food Manufacturers

For ingredient buyers, the practical implication is that precision-fermented dairy proteins are moving from proof-of-concept toward genuine sourcing options, at least for beta-lactoglobulin specifically. Companies formulating sports nutrition, medical nutrition or premium dairy-alternative products now have multiple credible suppliers to evaluate, not just one.

That said, commercial availability and commercial competitiveness are not the same thing. Precision-fermented proteins still typically carry a cost premium over conventional dairy proteins, and supply volumes remain a fraction of what traditional dairy processing can deliver. Buyers should treat current offerings as suited to premium, functionality-driven applications rather than commodity-scale substitution, at least for now.

The Bigger Structural Question

The more interesting long-term question may not be whether precision fermentation can match dairy on price, but whether it needs to. Beta-lactoglobulin’s appeal partly rests on functional and nutritional properties, including favourable amino acid composition for muscle protein synthesis, that could justify premium positioning independent of any sustainability argument.

If that thesis holds, precision fermentation’s near-term commercial path may run through performance nutrition, active ageing and medical nutrition categories willing to pay for functionality, rather than through mainstream dairy aisles competing purely on cost.

---

Sources

1. 21st.Bio. 21st.BIO Secures Self-GRAS Status for Its Precision Fermented Beta-Lactoglobulin. September 4, 2024.
2. Green Queen. 21st.Bio Earns Self-Affirmed GRAS Status in US for Precision-Fermented Whey Protein.
3. Green Queen. 21st.Bio Unveils Platform for Low-Cost Production of Cow-Free Dairy Protein.
4. Green Queen. New Scientific Review Highlights Beta-Lactoglobulin’s Dual Benefits for Metabolic and Muscle Health.
5. The Business Research Company. Precision Fermentation Dairy Global Market Report 2026.